Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

John S. Macdonald, Jacqueline K. Benedetti, Manuel Modiano, David S Alberts

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalInvestigational New Drugs
Volume15
Issue number4
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Topotecan
Colorectal Neoplasms
Topoisomerase I Inhibitors
Agranulocytosis
Kaplan-Meier Estimate
Thrombocytopenia
Appointments and Schedules
Confidence Intervals
Drug Therapy
Survival

Keywords

  • Colorectal cancer
  • Topoisomerase-1 inhibitor
  • Topotecan

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). / Macdonald, John S.; Benedetti, Jacqueline K.; Modiano, Manuel; Alberts, David S.

In: Investigational New Drugs, Vol. 15, No. 4, 1997, p. 357-359.

Research output: Contribution to journalArticle

@article{6f5625fb82f64eccb341116ad83f7698,
title = "Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)",
abstract = "The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40{\%}) patients having grade IV granulocytopenia and 4 out of 48 (8{\%}) patients demonstrating grade IV thrombocytopenia. Two patients (4{\%}) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95{\%} confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.",
keywords = "Colorectal cancer, Topoisomerase-1 inhibitor, Topotecan",
author = "Macdonald, {John S.} and Benedetti, {Jacqueline K.} and Manuel Modiano and Alberts, {David S}",
year = "1997",
doi = "10.1023/A:1005941603420",
language = "English (US)",
volume = "15",
pages = "357--359",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

AU - Macdonald, John S.

AU - Benedetti, Jacqueline K.

AU - Modiano, Manuel

AU - Alberts, David S

PY - 1997

Y1 - 1997

N2 - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

AB - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

KW - Colorectal cancer

KW - Topoisomerase-1 inhibitor

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0031424630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031424630&partnerID=8YFLogxK

U2 - 10.1023/A:1005941603420

DO - 10.1023/A:1005941603420

M3 - Article

C2 - 9547679

AN - SCOPUS:0031424630

VL - 15

SP - 357

EP - 359

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -